ETF Holdings Breakdown of ALLO

ALLO institutional holdings

The adjusted close for ALLO on 2025-11-12 was 1.23

The following institutional investment holdings of ALLO have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-12	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	141,203	USD 173,680	1.23
2025-11-12	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	141,203	USD 173,680	1.23
Total =		282,406	USD 347,360

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with ALLO

Analysts Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Target Price at $8.44

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has received a consensus rating of “Moderate Buy” from the twelve brokerages that are currently covering the stock, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month target price among brokerages […] - 2025-09-08 02:18:43

Mitsubishi UFJ Asset Management Co. Ltd. Grows Stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 4.1% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 264,065 shares of the company’s stock after buying an additional 10,489 shares during the quarter. Mitsubishi UFJ […] - 2025-08-14 05:33:06

Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) PT at $8.44

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twelve analysts that are currently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average […] - 2025-08-14 02:15:04

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month […] - 2025-07-17 05:10:53

Vontobel Holding Ltd. Decreases Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Vontobel Holding Ltd. reduced its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 5.0% in the 1st quarter, Holdings Channel.com reports. The firm owned 185,646 shares of the company’s stock after selling 9,811 shares during the period. Vontobel Holding Ltd.’s holdings in Allogene Therapeutics were worth $271,000 as of its most […] - 2025-07-09 05:02:59

Exchange Traded Concepts LLC Purchases 8,183 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Exchange Traded Concepts LLC lifted its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 13.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 68,858 shares of the company’s stock after purchasing an additional 8,183 shares during the period. […] - 2025-06-25 04:58:50

Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Price Target at $8.44

Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average […] - 2025-06-25 02:12:49

Ameriprise Financial Inc. Raises Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Ameriprise Financial Inc. lifted its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 14.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 201,943 shares of the company’s stock after acquiring an additional 24,830 shares during the quarter. Ameriprise Financial Inc.’s holdings in Allogene Therapeutics were worth $430,000 as of its […] - 2025-06-05 04:22:51

Allogene Therapeutics (NASDAQ:ALLO) Stock Rating Lowered by Citizens Jmp

Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) was downgraded by research analysts at Citizens Jmp from an “outperform” rating to a “market perform” rating in a research note issued on Wednesday, Marketbeat reports. A number of other brokerages have also recently commented on ALLO. Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 […] - 2025-05-16 02:35:02

Allogene Therapeutics (NASDAQ:ALLO) Price Target Lowered to $7.00 at Piper Sandler

Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) had its price target decreased by Piper Sandler from $9.00 to $7.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. ALLO has been the subject of a number of other reports. Robert W. Baird decreased their target price on […] - 2025-05-16 02:34:58

Dimensional Fund Advisors LP Grows Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Dimensional Fund Advisors LP raised its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 30.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,561,626 shares of the company’s stock after purchasing an additional 831,146 shares during the quarter. Dimensional Fund Advisors […] - 2025-05-12 05:22:49

Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Target Price at $9.29

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year price […] - 2025-05-06 02:09:01

Legal & General Group Plc Decreases Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Legal & General Group Plc trimmed its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 11.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 112,235 shares of the company’s stock after selling 15,172 shares during the quarter. Legal & General Group Plc’s holdings in Allogene Therapeutics were worth $239,000 at the end […] - 2025-05-01 04:57:03

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. reduced its position in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 3.9% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 8,000,692 shares of the company’s stock after selling 327,007 shares during the period. Vanguard Group Inc.’s holdings in Allogene Therapeutics were worth $17,041,000 at the end […] - 2025-04-17 04:22:52

Brokerages Set Allogene Therapeutics, Inc. (NASDAQ:ALLO) Target Price at $9.29

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) has received an average rating of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 12 month price objective among […] - 2025-04-11 02:40:54

Allogene's ALLO-329 Granted Three FDA Fast Track Designations

(RTTNews) - Clinical-stage biotechnology company Allogene Therapeutics, Inc. (ALLO), Monday announced that ALLO-329, an investigational dual-targeted CD19/CD70 allogeneic CAR T, has received three Fast Track Designations (FTD) from the U.S. Food and Drug Administration (FDA) for - 2025-04-07 12:57:11

Teacher Retirement System of Texas Boosts Stock Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Teacher Retirement System of Texas raised its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Free Report) by 28.9% during the fourth quarter, Holdings Channel.com reports. The firm owned 43,877 shares of the company’s stock after purchasing an additional 9,839 shares during the quarter. Teacher Retirement System of Texas’ holdings in Allogene Therapeutics were worth $93,000 […] - 2025-04-03 04:16:48

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Up 16.2% in February

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 39,100,000 shares, a growth of 16.2% from the February 13th total of 33,660,000 shares. Based on an average daily trading volume, of 5,120,000 […] - 2025-03-21 04:58:44

Allogene Therapeutics (NASDAQ:ALLO) Price Target Lowered to $8.00 at HC Wainwright

Allogene Therapeutics (NASDAQ:ALLO – Free Report) had its price objective decreased by HC Wainwright from $9.00 to $8.00 in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. Other research analysts have also recently issued reports about the stock. Canaccord Genuity Group reissued a “buy” rating […] - 2025-03-20 05:44:59

Head to Head Analysis: Allogene Therapeutics (NASDAQ:ALLO) and DBV Technologies (NASDAQ:DBVT)

Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) and DBV Technologies (NASDAQ:DBVT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations. Analyst Ratings This is a breakdown of […] - 2025-02-24 04:14:49

Back to Listing

Disclaimer